Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality

Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339.

¹ Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden (G.S., L.H.L.).
² University of Glasgow, UK (N.S.).
³ Cardiology Division, Massachusetts General Hospital, and Baim Institute for Clinical Research, Boston (J.J.).
⁴ Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital (S.V.), University of Toronto, ON, Canada.
⁵ St. Michael's Hospital, Division of Cardiology (D.F.), University of Toronto, ON, Canada.
⁶ Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (C.Z.).
⁷ Boehringer Ingelheim International GmbH, Ingelheim, Germany (J.T.G., M.B.).
⁸ Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany (M.B.).
⁹ Boehringer Ingelheim Norway KS, Asker, Norway (A.P.O.).
¹⁰ Section of Endocrinology, Yale University School of Medicine, Yale-New Haven Hospital, CT (S.E.I.).
¹¹ Department of Internal Medicine I, Nephrology, University Hospital Würzburg, Germany (C.W.).
¹² Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital (B.Z.), University of Toronto, ON, Canada.
¹³ Department of Medicine, University of Mississippi, Jackson (J.B.).

No abstract available

Keywords: heart failure; hospitalization; mortality.

Publication types